Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Alfentanil + propofol is a combination of two intravenous agents commonly used for procedural sedation and anesthesia. Alfentanil is a short-acting synthetic opioid analgesic that acts primarily as an agonist at the mu-type opioid receptor, providing potent analgesia and sedation. Propofol is a sedative-hypnotic agent that acts as a positive allosteric modulator of the gamma-aminobutyric acid type A (GABA-A) receptor, producing rapid onset hypnosis and amnesia. When used together, these drugs exhibit synergistic effects, resulting in greater sedation and analgesia than either drug alone. The combination allows for lower doses of each agent, potentially reducing side effects such as nausea or prolonged recovery time. Propofol can offset some emetic effects of alfentanil, while both drugs contribute to respiratory depression and hemodynamic changes; careful monitoring is required during administration[1][4][5]. This regimen is widely utilized in outpatient procedures due to its rapid onset/offset profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on alfentanil + propofol.